Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of Rockwell Medical, Inc., AAC Holdings, Inc., Dr. Reddy's Laboratories Ltd. and Biota Pharmaceuticals, Inc,; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights

Mar 02, 2016, 08:23 ET from Johnson & Weaver, LLP

$codeDebug.log("output array of get country targets countryT

SAN DIEGO, March 2, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Rockwell Medical, Inc., AAC Holdings, Inc., Dr. Reddy's Laboratories Ltd. and Biota Pharmaceuticals, Inc, as detailed below:

Rockwell Medical, Inc. 

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Rockwell Medical, Inc. (NASDAQ: RMTI) and certain of its officers and directors. On September 9, 2015, Rockwell Medical disclosed the U.S. commercial launch of Triferic, a FDA approved iron product designed to replace iron and preserve hemoglobin in hemodialysis patients in the United States. On February 29, 2016, Rockwell Medical's CFO Tom Klema revealed to investors on a conference call that sales of Triferic were "immaterial" for 2015; and in response analysts questioned the Company's commercial viability in the dialysis arena.

If you have information that could assist in this investigation, or if you are a Rockwell Medical shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

AAC Holdings, Inc.

Johnson & Weaver, LLP has commenced an investigation of possible claims against the Board of Directors of AAC Holdings, Inc. (NYSE: AAC). The investigation arises from the indictment of AAC's CEO and certain other employees on murder charges relating to the death of an AAC patient in 2010.

If you are a long-term AAC shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

Dr. Reddy's Laboratories Ltd.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and certain of its officers. On November 5, 2015, the Director of the FDA's Center for Drug Evaluation and Research sent a Warning Letter to Dr. Reddy's relating to inadequate quality controls at three key Indian facilities manufacturing raw pharmaceutical materials and oncology medicines. The FDA stated that Dr. Reddy's may not receive U.S. approvals for any new applications or supplements listing Dr. Reddy's as a drug product or API manufacturer, and that FDA may refuse admission into the U.S. of drugs manufactured at these three plants until the problems were fixed. 

If you are a Dr. Reddy's shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

Biota Pharmaceuticals, Inc.

Johnson & Weaver, LLP is investigating whether certain officers and directors of Biota Pharmaceuticals, Inc., (NASDAQ: BOTA) violated state or federal laws. On August 1, 2014 Biota announced its experimental influenza drug failed to meet the main goal in a mid-stage study. In April 2014 the U.S. Department of Health and Human Services pulled out of a contract to support the drug's development. The contract provided up to $231 million in financial support for the development of laninamivir octanoate for the treatment of influenza A and B in the United States.

If you have information that could assist in this investigation, including former employees and others, or if you are a Biota shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP Jim Baker, 619-814-4471 jimb@johnsonandweaver.com

Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO

 

SOURCE Johnson & Weaver, LLP



RELATED LINKS

http://www.johnsonandweaver.com